STAT3 and prostate cancer: In present study, we utilized the TAMs/cancer cells co-culture system and proved that QL serum re-programmed the TAMs to M2 phenotype by targeting IL-6/STAT3 signaling pathway, resulting in restoring the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel.